List view / Grid view
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
A team has created a biosynthetic pathway for E. coli that allows the bacteria to produce a common arthritis drug.
1 March 2021 | By Bruker Scientific, LLC
Watch our free on-demand webinar that focuses on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.
Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
